Skip to main content
. 2022 Feb 1;13:449. doi: 10.1038/s41467-021-27918-w

Fig. 4. WID-BC-index performance in buccal samples and in other gynaecological cancer patients.

Fig. 4

a WID-BC-index versus immune cell proportion in matched buccal samples from the breast cancer internal validation set (n = 69 controls, n = 66 breast cancer cases). b ROC curve corresponding to matched buccal samples (n = 69 controls, n = 66 breast cancer cases). c WID-BC-index versus immune cell proportion in ovarian cancer cases and healthy controls (n = 297 controls, n = 242 ovarian cancer cases). d ROC curve corresponding to the ovarian cancer samples (n = 297 controls, n = 242 ovarian cancer cases). e WID-BC-index versus immune cell proportion in endometrial cancer cases (n = 297 controls, n = 217 endometrial cancer cases) and f the corresponding ROC curve (n = 297 controls, n = 217 endometrial cancer cases). Source data are provided as a Source Data file.